Palatin Technologies, Inc.

Equities

PTN

US6960775020

Biotechnology & Medical Research

Market Closed - Nyse 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
1.87 USD +16.88% Intraday chart for Palatin Technologies, Inc. +15.43% -53.02%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Health Care Stocks Decline Late Afternoon MT
Palatin Shares Skid After Dry Eye Drug Candidate Misses Part of Targets in Late-Stage Trial MT
Transcript : Palatin Technologies, Inc. - Special Call
Transcript : Palatin Technologies, Inc., Q2 2024 Operating Results Call, Feb 15, 2024
Palatin Technologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
Palatin Announces Database Lock for PL9643 Melody-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease CI
Palatin Technologies, Inc. Provides Corporate Update and Highlights Strategic Priorities for Year 2024 CI
Cosette Pharmaceuticals, Inc. acquired worldwide rights to Vyleesi from Palatin Technologies, Inc. for approximately $170 million. CI
Top Premarket Decliners MT
Transcript : Palatin Technologies, Inc., Q1 2024 Earnings Call, Nov 14, 2023
Palatin Technologies, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023 CI
Palatin Technologies, Inc. announced that it has received $5.000001 million in funding CI
Palatin Technologies, Inc. announced that it expects to receive $5.000001 million in funding CI
Palatin Technologies Says Preclinical Data for Weight-Loss Therapy Showed Body Weight Loss of Up to 5.1% MT
Palatin Technoloes, Inc. Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients CI
Palatin Technologies Gets Non-Compliance Notice From NYSE American MT
Transcript : Palatin Technologies, Inc., Q4 2023 Earnings Call, Sep 28, 2023
Earnings Flash (PTN) PALATIN TECHNOLOGIES Posts Q4 Revenue $1.8M, vs. Street Est of $1.4M MT
Palatin Technologies, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2023 CI
North American Morning Briefing : Rising Oil -2- DJ
North American Morning Briefing : The Post-Fed Selloff Continues DJ
Palatin Technologies, Inc. Completes Enrollment in Phase 3 Melody-1 Study of PL9643 for the Treatment of Patients with Dry Eye Disease CI
Palatin Technologies Launches Clinical Program Evaluating Combination of Bremelanotide, PDE5i to Treat Erectile Dysfunction MT
Palatin Technologies, Inc. Initiates Clinical Program for Bremelanotide Co-Formulated with A Pde5i for the Treatment of Ed in Patients Non-Responsive to Pde5i Treatment CI
Palatin Technologies, Inc.'s Vyleesi Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study CI
Chart Palatin Technologies, Inc.
More charts
Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with unmet medical need and commercial potential. Its new product development activities focus primarily on MC1r agonists, with potential to treat inflammatory and autoimmune diseases, such as dry eye disease, known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. It is also engaged developing peptides that are active at more than one melanocortin receptor, and MC4r peptide and small molecule agonists with potential utility in obesity and metabolic-related disorders, including rare disease and orphan indications. It has completed Phase III PL9643 clinical study for dry eye disease. It is also conducting Phase II study of oral PL8177 in patients with ulcerative colitis.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.87 USD
Average target price
9.333 USD
Spread / Average Target
+399.11%
Consensus
  1. Stock
  2. Equities
  3. Stock Palatin Technologies, Inc. - Nyse
  4. News Palatin Technologies, Inc.
  5. HC Wainwright Adjusts Price Target on Palatin Technologies to $70 From $5 After Reverse Stock Split, Maintains Buy Rating